38O - PD-L1 and PD-1 expression in molecularly selected non-small-cell lung cancer (NSCLC) patients

Date 27 March 2014
Event ELCC 2014
Session Proffered Papers 2 - Tumour biology and translational research
Topics Lung and other Thoracic Tumours
Pathology/Molecular Biology
Presenter Armida D'Incecco
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors A. D'Incecco1, M. Andreozzi2, V. Ludovini3, E. Rossi4, L. Landi5, G. Minuti5, G. Fontanini6, L. Crinò3, L. Terracciano2, F. Cappuzzo5
  • 1Istituto Toscano Tumori, Oncologia Medica, Ospedale Civile, Livorno, Italy, 57124 - Livorno/IT
  • 2Department Of Pathology, Basel Hospital University, Basel, Switzerland, Basel/CH
  • 3S.c. Oncologia Medica, Ospedale S. Maria della Misericordia, Perugia, Italy, Perugia/IT
  • 4Oncologia Medica, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy, Livorno/IT
  • 5Istituto Toscano Tumori, Oncologia Medica, Ospedale Civile, Livorno, Italy, Livorno/IT
  • 6Anatomia Patologica, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, Pisa/IT

Abstract

The programmed death 1 (PD-1) receptor is an inhibitory T-cell receptor with two known ligands, PD-L1 and PD-L2 (programmed death-ligand 1 and 2). Aim of the present study was to evaluate PD-L1 and PD-1 expression in a cohort of molecularly selected NSCLC patients.